- Home
- EDN vs TNGX Comparison
EDN vs TNGX Comparison
Compare EDN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDN
- TNGX
- Stock Information
- Founded
- EDN 1992
- TNGX 2014
- Country
- EDN Argentina
- TNGX United States
- Employees
- EDN N/A
- TNGX N/A
- Industry
- EDN Electric Utilities: Central
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EDN Utilities
- TNGX Health Care
- Exchange
- EDN Nasdaq
- TNGX Nasdaq
- Market Cap
- EDN 675.2M
- TNGX 723.2M
- IPO Year
- EDN 2007
- TNGX N/A
- Fundamental
- Price
- EDN $15.38
- TNGX $7.76
- Analyst Decision
- EDN
- TNGX Strong Buy
- Analyst Count
- EDN 0
- TNGX 6
- Target Price
- EDN N/A
- TNGX $10.00
- AVG Volume (30 Days)
- EDN 202.3K
- TNGX 2.6M
- Earning Date
- EDN 08-11-2025
- TNGX 11-05-2025
- Dividend Yield
- EDN N/A
- TNGX N/A
- EPS Growth
- EDN N/A
- TNGX N/A
- EPS
- EDN 0.21
- TNGX N/A
- Revenue
- EDN $1,911,272,136.00
- TNGX $24,296,000.00
- Revenue This Year
- EDN $37.74
- TNGX $20.42
- Revenue Next Year
- EDN $27.07
- TNGX N/A
- P/E Ratio
- EDN $4.06
- TNGX N/A
- Revenue Growth
- EDN 23.18
- TNGX N/A
- 52 Week Low
- EDN $14.38
- TNGX $1.03
- 52 Week High
- EDN $51.69
- TNGX $8.80
- Technical
- Relative Strength Index (RSI)
- EDN 36.20
- TNGX 54.87
- Support Level
- EDN $14.38
- TNGX $7.66
- Resistance Level
- EDN $20.70
- TNGX $8.80
- Average True Range (ATR)
- EDN 1.33
- TNGX 0.53
- MACD
- EDN 0.10
- TNGX -0.00
- Stochastic Oscillator
- EDN 15.87
- TNGX 48.51
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.